Skip to content

Immunovant, Inc. IMVT Other operating expenses

Other operating expenses at other companies

TG Therapeutics logo
TG TherapeuticsTGTX
$73.14M+89.0%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s other operating expenses?
Immunovant, Inc. (IMVT) reported other operating expenses of $159.55M in Q1 2026.
How has Immunovant, Inc.'s other operating expenses changed year-over-year?
Immunovant, Inc.'s other operating expenses increased by 40.2% year-over-year, from $113.83M to $159.55M.
What is the long-term trend for Immunovant, Inc.'s other operating expenses?
Over 4 years (2022 to 2026), Immunovant, Inc.'s other operating expenses has grown at a 35.9% compound annual growth rate (CAGR), from $156.03M to $532.9M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.